CN1324367A - 环状前塞波素衍生肽及其应用 - Google Patents

环状前塞波素衍生肽及其应用 Download PDF

Info

Publication number
CN1324367A
CN1324367A CN99812627A CN99812627A CN1324367A CN 1324367 A CN1324367 A CN 1324367A CN 99812627 A CN99812627 A CN 99812627A CN 99812627 A CN99812627 A CN 99812627A CN 1324367 A CN1324367 A CN 1324367A
Authority
CN
China
Prior art keywords
amino acid
peptide
acid
hydrophobic amino
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN99812627A
Other languages
English (en)
Chinese (zh)
Inventor
戴维·E·赖特
约翰·S·奥布赖恩
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Myelos Corp
Original Assignee
Myelos Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Myelos Corp filed Critical Myelos Corp
Publication of CN1324367A publication Critical patent/CN1324367A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CN99812627A 1998-08-28 1999-08-20 环状前塞波素衍生肽及其应用 Pending CN1324367A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9835998P 1998-08-28 1998-08-28
US60/098,359 1998-08-28

Publications (1)

Publication Number Publication Date
CN1324367A true CN1324367A (zh) 2001-11-28

Family

ID=22268937

Family Applications (1)

Application Number Title Priority Date Filing Date
CN99812627A Pending CN1324367A (zh) 1998-08-28 1999-08-20 环状前塞波素衍生肽及其应用

Country Status (13)

Country Link
EP (1) EP1105420A1 (cg-RX-API-DMAC10.html)
JP (2) JP4528443B2 (cg-RX-API-DMAC10.html)
KR (1) KR20010079695A (cg-RX-API-DMAC10.html)
CN (1) CN1324367A (cg-RX-API-DMAC10.html)
AU (1) AU751034B2 (cg-RX-API-DMAC10.html)
BR (1) BR9913490A (cg-RX-API-DMAC10.html)
CA (1) CA2341810A1 (cg-RX-API-DMAC10.html)
CZ (1) CZ2001655A3 (cg-RX-API-DMAC10.html)
HU (1) HUP0103265A3 (cg-RX-API-DMAC10.html)
IL (1) IL141586A0 (cg-RX-API-DMAC10.html)
PL (1) PL204359B1 (cg-RX-API-DMAC10.html)
WO (1) WO2000012553A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA200102489B (cg-RX-API-DMAC10.html)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100366286C (zh) * 2003-04-28 2008-02-06 常州南云科技有限公司 Saposin C-DOPS:一种抗癌新药
CN103275187A (zh) * 2013-06-14 2013-09-04 四川科伦新光生物科技开发有限公司 一种镇痛肽fi及其基因和应用

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5571787A (en) 1993-07-30 1996-11-05 Myelos Corporation Prosaposin as a neurotrophic factor
WO2000012553A1 (en) * 1998-08-28 2000-03-09 Myelos Corporation Cyclic prosaposin-derived peptides and uses thereof
AUPQ084899A0 (en) * 1999-06-08 1999-07-01 University Of Melbourne, The Neurotrophin agonists
IL137820A (en) * 2000-08-10 2009-06-15 S I S Shulov Inst For Science Pharmaceutical composition for topical administration comprising an analgesic peptide
CN101583346B (zh) 2006-04-28 2015-08-19 儿童医院医疗中心 用于穿膜药物递送系统的皂化蛋白c和相关蛋白及肽的促融合性质
CA2666953A1 (en) * 2006-10-20 2008-05-02 Children's Hospital Medical Center Spontaneous forming ellipsoidal phospholipid unilamellar vesicles
US11291616B2 (en) 2015-04-23 2022-04-05 The Procter And Gamble Company Delivery of surfactant soluble anti-dandruff agent
BR112018067494B1 (pt) 2016-03-03 2022-05-10 The Procter & Gamble Company Composição anticaspa em aerossol
EP3528774A1 (en) 2016-10-21 2019-08-28 The Procter and Gamble Company Concentrated shampoo dosage of foam designating hair volume benefits
JP6952768B2 (ja) 2016-10-21 2021-10-20 ザ プロクター アンド ギャンブル カンパニーＴｈｅ Ｐｒｏｃｔｅｒ ＆ Ｇａｍｂｌｅ Ｃｏｍｐａｎｙ 低粘度であり粘度低減剤を含む、安定なコンパクトシャンプー製品
EP3528896A1 (en) 2016-10-21 2019-08-28 The Procter & Gamble Company Concentrated shampoo dosage of foam for providing hair care benefits
US11154467B2 (en) 2016-10-21 2021-10-26 The Procter And Gamble Plaza Concentrated shampoo dosage of foam designating hair conditioning benefits
EP3528897A1 (en) 2016-10-21 2019-08-28 The Procter & Gamble Company Dosage of foam for delivering consumer desired dosage volume, surfactant amount, and scalp health agent amount in an optimal formulation space
EP3528894A1 (en) 2016-10-21 2019-08-28 The Procter and Gamble Company Concentrated shampoo dosage of foam for providing hair care benefits
CN109862944A (zh) 2016-10-21 2019-06-07 宝洁公司 用于以最佳制剂空间递送消费者所需的剂型体积和表面活性剂量的泡沫剂型
US11141370B2 (en) 2017-06-06 2021-10-12 The Procter And Gamble Company Hair compositions comprising a cationic polymer mixture and providing improved in-use wet feel
US11224567B2 (en) 2017-06-06 2022-01-18 The Procter And Gamble Company Hair compositions comprising a cationic polymer/silicone mixture providing improved in-use wet feel
US11679073B2 (en) 2017-06-06 2023-06-20 The Procter & Gamble Company Hair compositions providing improved in-use wet feel
EP4400092A3 (en) 2017-10-10 2024-10-16 The Procter & Gamble Company Compact shampoo composition with amino acid based anionic surfactants and cationic polymers
US10426713B2 (en) 2017-10-10 2019-10-01 The Procter And Gamble Company Method of treating hair or skin with a personal care composition in a foam form
JP6974928B2 (ja) 2017-10-10 2021-12-01 ザ プロクター アンド ギャンブル カンパニーThe Procter & Gamble Company コンパクトなシャンプー組成物
WO2019074989A1 (en) 2017-10-10 2019-04-18 The Procter & Gamble Company COMPACT SHAMPOO COMPOSITION CONTAINING SULFATE-FREE SURFACTANTS
CN111556743B (zh) 2017-12-20 2023-07-18 宝洁公司 包含硅氧烷聚合物的澄清洗发剂组合物
EP3813774A1 (en) 2018-06-29 2021-05-05 The Procter & Gamble Company Low surfactant aerosol antidandruff composition
US12226505B2 (en) 2018-10-25 2025-02-18 The Procter & Gamble Company Compositions having enhanced deposition of surfactant-soluble anti-dandruff agents
WO2021113583A1 (en) 2019-12-06 2021-06-10 The Procter & Gamble Company Sulfate free composition with enhanced deposition of scalp active
WO2021173203A1 (en) 2020-02-27 2021-09-02 The Procter & Gamble Company Anti-dandruff compositions with sulfur having enhanced efficacy and aesthetics
WO2022109094A1 (en) 2020-11-23 2022-05-27 The Procter & Gamble Company Personal care compositions free of sulfated surfactants
JP7768985B2 (ja) 2020-12-04 2025-11-12 ザ プロクター アンド ギャンブル カンパニー 悪臭低減物質を含むヘアケア組成物
US12409125B2 (en) 2021-05-14 2025-09-09 The Procter & Gamble Company Shampoo compositions containing a sulfate-free surfactant system and sclerotium gum thickener
US11986543B2 (en) 2021-06-01 2024-05-21 The Procter & Gamble Company Rinse-off compositions with a surfactant system that is substantially free of sulfate-based surfactants
CA3235522A1 (en) 2021-12-09 2023-06-15 The Procter & Gamble Company Sulfate free personal cleansing composition comprising effective preservation

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL106106A0 (en) * 1993-06-22 1993-10-20 Interpharm Lab Ltd Library of polymeric molecules and its preparation
US6271196B1 (en) * 1996-03-05 2001-08-07 Regents Of The University Of Ca Methods of alleviating neuropathic pain using prosaposin-derived peptides
WO2000012553A1 (en) * 1998-08-28 2000-03-09 Myelos Corporation Cyclic prosaposin-derived peptides and uses thereof

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100366286C (zh) * 2003-04-28 2008-02-06 常州南云科技有限公司 Saposin C-DOPS:一种抗癌新药
CN103275187A (zh) * 2013-06-14 2013-09-04 四川科伦新光生物科技开发有限公司 一种镇痛肽fi及其基因和应用
CN103275187B (zh) * 2013-06-14 2014-10-29 四川合泰新光生物科技有限公司 一种镇痛肽fi及其基因和应用

Also Published As

Publication number Publication date
CA2341810A1 (en) 2000-03-09
ZA200102489B (en) 2002-06-04
PL346346A1 (en) 2002-02-11
WO2000012553A1 (en) 2000-03-09
PL204359B1 (pl) 2010-01-29
AU751034B2 (en) 2002-08-08
CZ2001655A3 (cs) 2001-11-14
KR20010079695A (ko) 2001-08-22
JP2002523518A (ja) 2002-07-30
EP1105420A1 (en) 2001-06-13
JP4528443B2 (ja) 2010-08-18
HUP0103265A3 (en) 2002-09-30
HUP0103265A2 (hu) 2002-02-28
BR9913490A (pt) 2001-09-25
IL141586A0 (en) 2002-03-10
AU5690599A (en) 2000-03-21
JP2010150272A (ja) 2010-07-08

Similar Documents

Publication Publication Date Title
JP4528443B2 (ja) 環状プロサポシン由来のペプチドおよびその使用
AU734566B2 (en) Methods of alleviating neuropathic pain using prosaposin-derived peptides
US5703045A (en) Treating disorders by application of insulin-like growth factors and analogs
CA2058443C (en) Treating disorders by application of insulin-like growth factors and analogs
CN1452492A (zh) 神经保护肽
WO1997015593A1 (en) Neurotrophin antagonists
CN1723034A (zh) 治疗糖尿病的组合物和方法
JP2002500161A (ja) 神経栄養性および鎮痛性のレトロインバースペプチド
WO1998039357A1 (en) Method of alleviating neuropathic pain
US6723699B1 (en) Treating disorders by application of insulin-like growth factors and analogs
US6693076B1 (en) Treating disorders by application of insulin-like growth factors and analogs
WO1998042746A9 (en) Synthetic saposin c-derived neurotrophic peptides
EP0971956A2 (en) Synthetic saposin c-derived neurotrophic peptides
AU2002300005B2 (en) Method of alleviating neuropathic pain
JP2002544120A (ja) 逆・反転化プロサポシン由来ポリペプチドおよびその使用
MXPA01001966A (en) Cyclic prosaposin-derived peptides and uses thereof
MXPA98007245A (en) Methods to alleviate neuropathic pain using peptides derived from prosapos
HK1017612A (en) Treating disorders by application of insulin-like growth factors and analogs

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication